Infliximab Biosimilar - Research Grade

Product Specifications

Background

Infliximab biosimilar is a chimeric IgG1κ monoclonal antibody (composed of human constant and murine variable regions) specific for human tumor necrosis factor-alpha (TNFα) . It has a molecular weight of approximately 149.1 kilodaltons. Infliximab biosimilar is produced by a recombinant cell line cultured by suspension culture and is purified by a series of steps that includes measures to inactivate and remove viruses.

Product Name Alternative

Cachectin, TNFa, Tumor necrosis factor ligand superfamily member 2, Tnfsf2

UniProt

P01375

Host

Humanized

Reactivity

Human

Target

TNF alpha

Isotype

IgG1 κ

Sequence

https://www.imgt.org/mAb-DB/

Purification Method

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Concentration

1.0 - 5.0 mg/mL

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>95% by SDS-PAGE and HPLC

Buffer

ICH3001-100ml ICH3002-100ml ICH3003-100ml

Shipping Conditions

Blue ice

Storage Conditions

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.